share_log
Reuters ·  Mar 21 13:15
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 Pnh Clinical Trial Program
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 392

Recommended

Write a comment